Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODIN
2023-506613-22-00Phase 3Authorised
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of ticagrelor in coronary arteriosclerosis (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Hierarchical composite of death, stroke, myocardial infarction, repeat revascularization, and any graft failure at 1 year. Planned start Sep 2024; status: authorised.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-506613-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506613-22-00.